Fitness Trends Monobody Based Therapeutic Drugs Market

Monobody Based Therapeutic Drugs Market - Global
Industry Insights, Trends, Outlook, and Opportunity
Analysis, 2018-2026
Monobodies are synthetic binding proteins in which fibronectin type III domain (FN3) is used as
a molecular scaffold. Monobodies are robust alternative to antibodies to create target-binding
proteins. The term monobody was devised by Koide group in 1998. Monobody belong to a class
called antibody mimics aiming to overcome the shortcomings of natural antibody. A major
advantage of monobody is that it can be used as genetically encoded intracellular inhibitors.
Adnexus (now a part of Bristol-Myers Squibb), uses monobody technology to inhibit tumor
angiogenesis since 2007.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/43
Monobody – a technology with great potential in Cancer Treatment
Monobody is a technology which has great potential in the treatment of cancer. Monobody is
independent of their environment and can be used as genetically encoded inhibitors. When a
monobody binds to a protein then it work as an inhibitor of that protein.
Pegdinetanib, also known as Adnectin, is an antagonist of vascular endothelial growth factor
receptor 2 has entered in clinical trial II for the treatment of glioblastoma. Adnectins is based
on 10 th fibronectin type III domain designed to bind with high affinity and specificity to
relevant targets. There are three solvent accessible loops (BC, DE, and FG) which are
responsible for binding. Various monobody proteins have been developed for clinical efficacy
against cancer and infections. The market of monobody will be high in developed region like
America because of availability of advance medical technology, good medical facilities and
medical infrastructure.
Success of therapeutic antibodies has sparked a growing interest to create molecules that bind
to the target molecule specifically and efficiently. A common alternative process is that the
libraries of monobody being constructed which can be obtained by capturing natural diversity
of an antibody.